Spring Sale! Save 25
Free Express Shipping
Sale Ends: 06/06
Uses
Side effects
Interactions
Precautions
- ARICEPT is an acetylcholinesterase inhibitor indicated for the treatment of dementia of the Alzheimer’s type. Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer’s Disease.
- The most common adverse reactions in clinical studies of ARICEPT are nausea, diarrhea, insomnia, vomiting, muscle cramps, fatigue, and anorexia.
- Cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications.
- A synergistic effect may be expected with concomitant administration o f succinylcholine, similar neuromuscular blocking agents, or cholinergic agonists.
- Cholinesterase inhibitors are likely to exaggerate succinylcholine-type muscle relaxation during anesthesia.
- Cholinesterase inhibitors may have vagotonic effects on the sinoatrial and atrioventricular nodes manifesting as bradycardia or heart block.
- ARICEPT can cause vomiting. Patients should be observed closely at initiation of treatment and after dose increases.
- Patients should be monitored closely for symptoms of active or occult gastrointestinal (GI) bleeding, especially those at increased risk for developing ulcers.
- The use of ARICEPT in a dose of 23 mg once daily is associated with weight loss.
- Cholinomimetics may cause bladder outflow obstructions.
- Cholinomimetics are believed to have some potential to cause generalized convulsions.
- Cholinesterase inhibitors should be prescribed with care to patients with a history of asthma or obstructive pulmonary disease.
